Assessment of pioglitazone and proinflammatory cytokines during buprenorphine taper in patients with opioid use disorder View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2018-10

AUTHORS

Jennifer R. Schroeder, Karran A. Phillips, David H. Epstein, Michelle L. Jobes, Melody A. Furnari, Ashley P. Kennedy, Markus Heilig, Kenzie L. Preston

ABSTRACT

BACKGROUND: Preliminary evidence suggested that the PPARγ agonist pioglitazone reduces opioid-withdrawal symptoms, possibly by inhibiting increases in proinflammatory cytokines. METHODS: A randomized, placebo-controlled clinical trial was conducted utilizing two different study designs (entirely outpatient, and a combination of inpatient and outpatient) to evaluate the safety and efficacy of pioglitazone as an adjunct medication for people with opioid physical dependence undergoing a buprenorphine taper. Participants were stabilized on buprenorphine/naloxone (sublingual, up to 16/4 mg/day), then randomized to receive oral pioglitazone (up to 45 mg/day) or placebo before, during, and after buprenorphine taper. Outcome measures included the Subjective Opiate Withdrawal Scale (SOWS) and Clinical Opiate Withdrawal Scale, use of rescue medications to alleviate opioid withdrawal symptoms, and opioid-positive urine specimens. Cerebrospinal fluid (CSF) and plasma were collected during the taper in a subset of participants for measurement of proinflammatory cytokines. RESULTS: The clinical trial was prematurely terminated due to slow enrollment; 40 participants per group were required for adequate statistical power to test study hypotheses. Twenty-four participants enrolled; 17 received at least one dose of study medication (6 pioglitazone, 11 placebo). SOWS scores were higher in the pioglitazone arm than in the placebo arm after adjusting for use of rescue medications; participants in the pioglitazone arm needed more rescue medications than the placebo arm during the post-taper phase. SOWS scores were positively correlated with monocyte chemoattractant protein-1 (MCP-1) in CSF (r = 0.70, p = 0.038) and plasma (r = 0.77, p = 0.015). Participants having higher levels of plasma MCP-1 reported higher SOWS, most notably after the buprenorphine taper ended. CONCLUSIONS: Results from this study provide no evidence that pioglitazone reduces opioid withdrawal symptoms during buprenorphine taper. High correlations between MCP-1 and opioid withdrawal symptoms support a role of proinflammatory processes in opioid withdrawal. TRIAL REGISTRATION: clinicaltrials.gov identifier: NCT01517165. More... »

PAGES

2957-2966

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s00213-018-4986-5

DOI

http://dx.doi.org/10.1007/s00213-018-4986-5

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1106008490

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/30079432


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Johns Hopkins Bayview Medical Center", 
          "id": "https://www.grid.ac/institutes/grid.411940.9", 
          "name": [
            "Johns Hopkins Bayview Medical Center, 21224, Baltimore, MD, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Schroeder", 
        "givenName": "Jennifer R.", 
        "id": "sg:person.0737140614.98", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0737140614.98"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "National Institute on Drug Abuse", 
          "id": "https://www.grid.ac/institutes/grid.420090.f", 
          "name": [
            "National Institute on Drug Abuse, Intramural Research Program, National Institutes of Health, 251 Bayview Blvd., BRC Building, Suite 200, 21224, Baltimore, MD, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Phillips", 
        "givenName": "Karran A.", 
        "id": "sg:person.01102463545.22", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01102463545.22"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "National Institute on Drug Abuse", 
          "id": "https://www.grid.ac/institutes/grid.420090.f", 
          "name": [
            "National Institute on Drug Abuse, Intramural Research Program, National Institutes of Health, 251 Bayview Blvd., BRC Building, Suite 200, 21224, Baltimore, MD, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Epstein", 
        "givenName": "David H.", 
        "id": "sg:person.01352571246.35", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01352571246.35"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "National Institute on Drug Abuse", 
          "id": "https://www.grid.ac/institutes/grid.420090.f", 
          "name": [
            "National Institute on Drug Abuse, Intramural Research Program, National Institutes of Health, 251 Bayview Blvd., BRC Building, Suite 200, 21224, Baltimore, MD, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Jobes", 
        "givenName": "Michelle L.", 
        "id": "sg:person.01303364144.10", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01303364144.10"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "National Institute on Drug Abuse", 
          "id": "https://www.grid.ac/institutes/grid.420090.f", 
          "name": [
            "National Institute on Drug Abuse, Intramural Research Program, National Institutes of Health, 251 Bayview Blvd., BRC Building, Suite 200, 21224, Baltimore, MD, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Furnari", 
        "givenName": "Melody A.", 
        "id": "sg:person.0646122646.72", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0646122646.72"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "National Institute on Drug Abuse", 
          "id": "https://www.grid.ac/institutes/grid.420090.f", 
          "name": [
            "National Institute on Drug Abuse, Intramural Research Program, National Institutes of Health, 251 Bayview Blvd., BRC Building, Suite 200, 21224, Baltimore, MD, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kennedy", 
        "givenName": "Ashley P.", 
        "id": "sg:person.01146316617.51", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01146316617.51"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Link\u00f6ping University", 
          "id": "https://www.grid.ac/institutes/grid.5640.7", 
          "name": [
            "Center for Social and Affective Neuroscience, IKE, Link\u00f6ping Univ, 58183, Link\u00f6ping, Sweden"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Heilig", 
        "givenName": "Markus", 
        "id": "sg:person.01310670153.54", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01310670153.54"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "National Institute on Drug Abuse", 
          "id": "https://www.grid.ac/institutes/grid.420090.f", 
          "name": [
            "National Institute on Drug Abuse, Intramural Research Program, National Institutes of Health, 251 Bayview Blvd., BRC Building, Suite 200, 21224, Baltimore, MD, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Preston", 
        "givenName": "Kenzie L.", 
        "id": "sg:person.0710216340.36", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0710216340.36"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1111/adb.12471", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003181460"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/adb.12471", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003181460"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/acer.12091", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1004311066"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.biopsych.2010.12.010", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1008080755"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3109/00952998709001515", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1009252117"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/acer.12367", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012437820"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00210-014-0996-y", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012643033", 
          "https://doi.org/10.1007/s00210-014-0996-y"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.npp.1301213", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013042291", 
          "https://doi.org/10.1038/sj.npp.1301213"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.npp.1301213", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013042291", 
          "https://doi.org/10.1038/sj.npp.1301213"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1001/archpsyc.1985.01790340041006", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1020424635"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1001/jamainternmed.2014.5302", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1020428139"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1146/annurev.med.53.082901.104018", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1024565972"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.brainres.2012.12.035", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1028235225"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.physbeh.2015.10.006", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1030367467"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.bbi.2008.09.012", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031591782"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1100/tsw.2007.230", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1035564279"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.tips.2009.08.002", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037523582"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.bbr.2009.09.034", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038519026"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.bbr.2008.10.010", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1039814960"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/acer.12610", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1040088953"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00213-016-4452-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1047185141", 
          "https://doi.org/10.1007/s00213-016-4452-1"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00213-016-4452-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1047185141", 
          "https://doi.org/10.1007/s00213-016-4452-1"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00213-016-4452-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1047185141", 
          "https://doi.org/10.1007/s00213-016-4452-1"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1080/02791072.2003.10400007", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1048705737"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.bbi.2009.01.014", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1051963937"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1055/s-0033-1364035", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1057304351"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3892/etm.2016.3979", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1071504896"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1075026057", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/add.13868", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1085453121"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.pbb.2017.10.002", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1092180260"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2018-10", 
    "datePublishedReg": "2018-10-01", 
    "description": "BACKGROUND: Preliminary evidence suggested that the PPAR\u03b3 agonist pioglitazone reduces opioid-withdrawal symptoms, possibly by inhibiting increases in proinflammatory cytokines.\nMETHODS: A randomized, placebo-controlled clinical trial was conducted utilizing two different study designs (entirely outpatient, and a combination of inpatient and outpatient) to evaluate the safety and efficacy of pioglitazone as an adjunct medication for people with opioid physical dependence undergoing a buprenorphine taper. Participants were stabilized on buprenorphine/naloxone (sublingual, up to 16/4\u00a0mg/day), then randomized to receive oral pioglitazone (up to 45\u00a0mg/day) or placebo before, during, and after buprenorphine taper. Outcome measures included the Subjective Opiate Withdrawal Scale (SOWS) and Clinical Opiate Withdrawal Scale, use of rescue medications to alleviate opioid withdrawal symptoms, and opioid-positive urine specimens. Cerebrospinal fluid (CSF) and plasma were collected during the taper in a subset of participants for measurement of proinflammatory cytokines.\nRESULTS: The clinical trial was prematurely terminated due to slow enrollment; 40 participants per group were required for adequate statistical power to test study hypotheses. Twenty-four participants enrolled; 17 received at least one dose of study medication (6 pioglitazone, 11 placebo). SOWS scores were higher in the pioglitazone arm than in the placebo arm after adjusting for use of rescue medications; participants in the pioglitazone arm needed more rescue medications than the placebo arm during the post-taper phase. SOWS scores were positively correlated with monocyte chemoattractant protein-1 (MCP-1) in CSF (r\u2009=\u20090.70, p\u2009=\u20090.038) and plasma (r\u2009=\u20090.77, p\u2009=\u20090.015). Participants having higher levels of plasma MCP-1 reported higher SOWS, most notably after the buprenorphine taper ended.\nCONCLUSIONS: Results from this study provide no evidence that pioglitazone reduces opioid withdrawal symptoms during buprenorphine taper. High correlations between MCP-1 and opioid withdrawal symptoms support a role of proinflammatory processes in opioid withdrawal.\nTRIAL REGISTRATION: clinicaltrials.gov identifier: NCT01517165.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/s00213-018-4986-5", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isFundedItemOf": [
      {
        "id": "sg:grant.2715425", 
        "type": "MonetaryGrant"
      }
    ], 
    "isPartOf": [
      {
        "id": "sg:journal.1085440", 
        "issn": [
          "0033-3158", 
          "1432-2072"
        ], 
        "name": "Psychopharmacology", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "10", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "235"
      }
    ], 
    "name": "Assessment of pioglitazone and proinflammatory cytokines during buprenorphine taper in patients with opioid use disorder", 
    "pagination": "2957-2966", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "b218ac4d3bdc06e6a0f16732334d35d5485bd84bf28689b82873f25e2f571b83"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "30079432"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "7608025"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s00213-018-4986-5"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1106008490"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s00213-018-4986-5", 
      "https://app.dimensions.ai/details/publication/pub.1106008490"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-10T18:29", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8675_00000573.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://link.springer.com/10.1007%2Fs00213-018-4986-5"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00213-018-4986-5'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00213-018-4986-5'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00213-018-4986-5'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00213-018-4986-5'


 

This table displays all metadata directly associated to this object as RDF triples.

206 TRIPLES      21 PREDICATES      55 URIs      21 LITERALS      9 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s00213-018-4986-5 schema:about anzsrc-for:11
2 anzsrc-for:1103
3 schema:author Nbbc82053a8164849abd1d8adc54b4423
4 schema:citation sg:pub.10.1007/s00210-014-0996-y
5 sg:pub.10.1007/s00213-016-4452-1
6 sg:pub.10.1038/sj.npp.1301213
7 https://app.dimensions.ai/details/publication/pub.1075026057
8 https://doi.org/10.1001/archpsyc.1985.01790340041006
9 https://doi.org/10.1001/jamainternmed.2014.5302
10 https://doi.org/10.1016/j.bbi.2008.09.012
11 https://doi.org/10.1016/j.bbi.2009.01.014
12 https://doi.org/10.1016/j.bbr.2008.10.010
13 https://doi.org/10.1016/j.bbr.2009.09.034
14 https://doi.org/10.1016/j.biopsych.2010.12.010
15 https://doi.org/10.1016/j.brainres.2012.12.035
16 https://doi.org/10.1016/j.pbb.2017.10.002
17 https://doi.org/10.1016/j.physbeh.2015.10.006
18 https://doi.org/10.1016/j.tips.2009.08.002
19 https://doi.org/10.1055/s-0033-1364035
20 https://doi.org/10.1080/02791072.2003.10400007
21 https://doi.org/10.1100/tsw.2007.230
22 https://doi.org/10.1111/acer.12091
23 https://doi.org/10.1111/acer.12367
24 https://doi.org/10.1111/acer.12610
25 https://doi.org/10.1111/adb.12471
26 https://doi.org/10.1111/add.13868
27 https://doi.org/10.1146/annurev.med.53.082901.104018
28 https://doi.org/10.3109/00952998709001515
29 https://doi.org/10.3892/etm.2016.3979
30 schema:datePublished 2018-10
31 schema:datePublishedReg 2018-10-01
32 schema:description BACKGROUND: Preliminary evidence suggested that the PPARγ agonist pioglitazone reduces opioid-withdrawal symptoms, possibly by inhibiting increases in proinflammatory cytokines. METHODS: A randomized, placebo-controlled clinical trial was conducted utilizing two different study designs (entirely outpatient, and a combination of inpatient and outpatient) to evaluate the safety and efficacy of pioglitazone as an adjunct medication for people with opioid physical dependence undergoing a buprenorphine taper. Participants were stabilized on buprenorphine/naloxone (sublingual, up to 16/4 mg/day), then randomized to receive oral pioglitazone (up to 45 mg/day) or placebo before, during, and after buprenorphine taper. Outcome measures included the Subjective Opiate Withdrawal Scale (SOWS) and Clinical Opiate Withdrawal Scale, use of rescue medications to alleviate opioid withdrawal symptoms, and opioid-positive urine specimens. Cerebrospinal fluid (CSF) and plasma were collected during the taper in a subset of participants for measurement of proinflammatory cytokines. RESULTS: The clinical trial was prematurely terminated due to slow enrollment; 40 participants per group were required for adequate statistical power to test study hypotheses. Twenty-four participants enrolled; 17 received at least one dose of study medication (6 pioglitazone, 11 placebo). SOWS scores were higher in the pioglitazone arm than in the placebo arm after adjusting for use of rescue medications; participants in the pioglitazone arm needed more rescue medications than the placebo arm during the post-taper phase. SOWS scores were positively correlated with monocyte chemoattractant protein-1 (MCP-1) in CSF (r = 0.70, p = 0.038) and plasma (r = 0.77, p = 0.015). Participants having higher levels of plasma MCP-1 reported higher SOWS, most notably after the buprenorphine taper ended. CONCLUSIONS: Results from this study provide no evidence that pioglitazone reduces opioid withdrawal symptoms during buprenorphine taper. High correlations between MCP-1 and opioid withdrawal symptoms support a role of proinflammatory processes in opioid withdrawal. TRIAL REGISTRATION: clinicaltrials.gov identifier: NCT01517165.
33 schema:genre research_article
34 schema:inLanguage en
35 schema:isAccessibleForFree false
36 schema:isPartOf N1b2c7ed4b1d54ea6abe34d4c71cd0151
37 Nce34bb4419f54e7cb8332f241086d519
38 sg:journal.1085440
39 schema:name Assessment of pioglitazone and proinflammatory cytokines during buprenorphine taper in patients with opioid use disorder
40 schema:pagination 2957-2966
41 schema:productId N3420055ae8d04ebaa45a357635e6e7b1
42 N4c33ab73aac84a14a3f38dbf8285a11a
43 N9324cd1a18f34e01b28e2ddb21dc3565
44 Nc5217deabb184b82b4e0bb37a2e4a940
45 Nc9a14c5e406146c8a33bfb16277b60bf
46 schema:sameAs https://app.dimensions.ai/details/publication/pub.1106008490
47 https://doi.org/10.1007/s00213-018-4986-5
48 schema:sdDatePublished 2019-04-10T18:29
49 schema:sdLicense https://scigraph.springernature.com/explorer/license/
50 schema:sdPublisher Nd954e4fbdc9943128ac5cbdd0000d711
51 schema:url https://link.springer.com/10.1007%2Fs00213-018-4986-5
52 sgo:license sg:explorer/license/
53 sgo:sdDataset articles
54 rdf:type schema:ScholarlyArticle
55 N0693c73024684f8b8bbc25369874608f rdf:first sg:person.01303364144.10
56 rdf:rest Nf2e989e7a80a43c7aa1097998776384a
57 N0950e6ec90f742299440eb884f2126b4 rdf:first sg:person.0710216340.36
58 rdf:rest rdf:nil
59 N1b2c7ed4b1d54ea6abe34d4c71cd0151 schema:issueNumber 10
60 rdf:type schema:PublicationIssue
61 N3420055ae8d04ebaa45a357635e6e7b1 schema:name nlm_unique_id
62 schema:value 7608025
63 rdf:type schema:PropertyValue
64 N4c33ab73aac84a14a3f38dbf8285a11a schema:name dimensions_id
65 schema:value pub.1106008490
66 rdf:type schema:PropertyValue
67 N7edeee6e15064afcbc5c7b5273d92aa0 rdf:first sg:person.01146316617.51
68 rdf:rest Ndfc0ef5b9cf74e16bca45b74ad40199f
69 N9324cd1a18f34e01b28e2ddb21dc3565 schema:name pubmed_id
70 schema:value 30079432
71 rdf:type schema:PropertyValue
72 Nbbc82053a8164849abd1d8adc54b4423 rdf:first sg:person.0737140614.98
73 rdf:rest Ne22dcb0cde854a9880737add2b0bd952
74 Nc5217deabb184b82b4e0bb37a2e4a940 schema:name doi
75 schema:value 10.1007/s00213-018-4986-5
76 rdf:type schema:PropertyValue
77 Nc9a14c5e406146c8a33bfb16277b60bf schema:name readcube_id
78 schema:value b218ac4d3bdc06e6a0f16732334d35d5485bd84bf28689b82873f25e2f571b83
79 rdf:type schema:PropertyValue
80 Nce34bb4419f54e7cb8332f241086d519 schema:volumeNumber 235
81 rdf:type schema:PublicationVolume
82 Nd954e4fbdc9943128ac5cbdd0000d711 schema:name Springer Nature - SN SciGraph project
83 rdf:type schema:Organization
84 Nde0bcc54a41344edbfe9fe12570264a7 rdf:first sg:person.01352571246.35
85 rdf:rest N0693c73024684f8b8bbc25369874608f
86 Ndfc0ef5b9cf74e16bca45b74ad40199f rdf:first sg:person.01310670153.54
87 rdf:rest N0950e6ec90f742299440eb884f2126b4
88 Ne22dcb0cde854a9880737add2b0bd952 rdf:first sg:person.01102463545.22
89 rdf:rest Nde0bcc54a41344edbfe9fe12570264a7
90 Nf2e989e7a80a43c7aa1097998776384a rdf:first sg:person.0646122646.72
91 rdf:rest N7edeee6e15064afcbc5c7b5273d92aa0
92 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
93 schema:name Medical and Health Sciences
94 rdf:type schema:DefinedTerm
95 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
96 schema:name Clinical Sciences
97 rdf:type schema:DefinedTerm
98 sg:grant.2715425 http://pending.schema.org/fundedItem sg:pub.10.1007/s00213-018-4986-5
99 rdf:type schema:MonetaryGrant
100 sg:journal.1085440 schema:issn 0033-3158
101 1432-2072
102 schema:name Psychopharmacology
103 rdf:type schema:Periodical
104 sg:person.01102463545.22 schema:affiliation https://www.grid.ac/institutes/grid.420090.f
105 schema:familyName Phillips
106 schema:givenName Karran A.
107 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01102463545.22
108 rdf:type schema:Person
109 sg:person.01146316617.51 schema:affiliation https://www.grid.ac/institutes/grid.420090.f
110 schema:familyName Kennedy
111 schema:givenName Ashley P.
112 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01146316617.51
113 rdf:type schema:Person
114 sg:person.01303364144.10 schema:affiliation https://www.grid.ac/institutes/grid.420090.f
115 schema:familyName Jobes
116 schema:givenName Michelle L.
117 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01303364144.10
118 rdf:type schema:Person
119 sg:person.01310670153.54 schema:affiliation https://www.grid.ac/institutes/grid.5640.7
120 schema:familyName Heilig
121 schema:givenName Markus
122 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01310670153.54
123 rdf:type schema:Person
124 sg:person.01352571246.35 schema:affiliation https://www.grid.ac/institutes/grid.420090.f
125 schema:familyName Epstein
126 schema:givenName David H.
127 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01352571246.35
128 rdf:type schema:Person
129 sg:person.0646122646.72 schema:affiliation https://www.grid.ac/institutes/grid.420090.f
130 schema:familyName Furnari
131 schema:givenName Melody A.
132 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0646122646.72
133 rdf:type schema:Person
134 sg:person.0710216340.36 schema:affiliation https://www.grid.ac/institutes/grid.420090.f
135 schema:familyName Preston
136 schema:givenName Kenzie L.
137 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0710216340.36
138 rdf:type schema:Person
139 sg:person.0737140614.98 schema:affiliation https://www.grid.ac/institutes/grid.411940.9
140 schema:familyName Schroeder
141 schema:givenName Jennifer R.
142 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0737140614.98
143 rdf:type schema:Person
144 sg:pub.10.1007/s00210-014-0996-y schema:sameAs https://app.dimensions.ai/details/publication/pub.1012643033
145 https://doi.org/10.1007/s00210-014-0996-y
146 rdf:type schema:CreativeWork
147 sg:pub.10.1007/s00213-016-4452-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047185141
148 https://doi.org/10.1007/s00213-016-4452-1
149 rdf:type schema:CreativeWork
150 sg:pub.10.1038/sj.npp.1301213 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013042291
151 https://doi.org/10.1038/sj.npp.1301213
152 rdf:type schema:CreativeWork
153 https://app.dimensions.ai/details/publication/pub.1075026057 schema:CreativeWork
154 https://doi.org/10.1001/archpsyc.1985.01790340041006 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020424635
155 rdf:type schema:CreativeWork
156 https://doi.org/10.1001/jamainternmed.2014.5302 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020428139
157 rdf:type schema:CreativeWork
158 https://doi.org/10.1016/j.bbi.2008.09.012 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031591782
159 rdf:type schema:CreativeWork
160 https://doi.org/10.1016/j.bbi.2009.01.014 schema:sameAs https://app.dimensions.ai/details/publication/pub.1051963937
161 rdf:type schema:CreativeWork
162 https://doi.org/10.1016/j.bbr.2008.10.010 schema:sameAs https://app.dimensions.ai/details/publication/pub.1039814960
163 rdf:type schema:CreativeWork
164 https://doi.org/10.1016/j.bbr.2009.09.034 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038519026
165 rdf:type schema:CreativeWork
166 https://doi.org/10.1016/j.biopsych.2010.12.010 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008080755
167 rdf:type schema:CreativeWork
168 https://doi.org/10.1016/j.brainres.2012.12.035 schema:sameAs https://app.dimensions.ai/details/publication/pub.1028235225
169 rdf:type schema:CreativeWork
170 https://doi.org/10.1016/j.pbb.2017.10.002 schema:sameAs https://app.dimensions.ai/details/publication/pub.1092180260
171 rdf:type schema:CreativeWork
172 https://doi.org/10.1016/j.physbeh.2015.10.006 schema:sameAs https://app.dimensions.ai/details/publication/pub.1030367467
173 rdf:type schema:CreativeWork
174 https://doi.org/10.1016/j.tips.2009.08.002 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037523582
175 rdf:type schema:CreativeWork
176 https://doi.org/10.1055/s-0033-1364035 schema:sameAs https://app.dimensions.ai/details/publication/pub.1057304351
177 rdf:type schema:CreativeWork
178 https://doi.org/10.1080/02791072.2003.10400007 schema:sameAs https://app.dimensions.ai/details/publication/pub.1048705737
179 rdf:type schema:CreativeWork
180 https://doi.org/10.1100/tsw.2007.230 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035564279
181 rdf:type schema:CreativeWork
182 https://doi.org/10.1111/acer.12091 schema:sameAs https://app.dimensions.ai/details/publication/pub.1004311066
183 rdf:type schema:CreativeWork
184 https://doi.org/10.1111/acer.12367 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012437820
185 rdf:type schema:CreativeWork
186 https://doi.org/10.1111/acer.12610 schema:sameAs https://app.dimensions.ai/details/publication/pub.1040088953
187 rdf:type schema:CreativeWork
188 https://doi.org/10.1111/adb.12471 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003181460
189 rdf:type schema:CreativeWork
190 https://doi.org/10.1111/add.13868 schema:sameAs https://app.dimensions.ai/details/publication/pub.1085453121
191 rdf:type schema:CreativeWork
192 https://doi.org/10.1146/annurev.med.53.082901.104018 schema:sameAs https://app.dimensions.ai/details/publication/pub.1024565972
193 rdf:type schema:CreativeWork
194 https://doi.org/10.3109/00952998709001515 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009252117
195 rdf:type schema:CreativeWork
196 https://doi.org/10.3892/etm.2016.3979 schema:sameAs https://app.dimensions.ai/details/publication/pub.1071504896
197 rdf:type schema:CreativeWork
198 https://www.grid.ac/institutes/grid.411940.9 schema:alternateName Johns Hopkins Bayview Medical Center
199 schema:name Johns Hopkins Bayview Medical Center, 21224, Baltimore, MD, USA
200 rdf:type schema:Organization
201 https://www.grid.ac/institutes/grid.420090.f schema:alternateName National Institute on Drug Abuse
202 schema:name National Institute on Drug Abuse, Intramural Research Program, National Institutes of Health, 251 Bayview Blvd., BRC Building, Suite 200, 21224, Baltimore, MD, USA
203 rdf:type schema:Organization
204 https://www.grid.ac/institutes/grid.5640.7 schema:alternateName Linköping University
205 schema:name Center for Social and Affective Neuroscience, IKE, Linköping Univ, 58183, Linköping, Sweden
206 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...